MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Amarin Corporation plc Total Assets 2011-2026 | AMRN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Amarin Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 671 M | 685 M | 832 M | 886 M | 1.07 B | 966 M | 882 M | 386 M | 162 M | 167 M | 173 M | 171 M | 252 M | 311 M | 126 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 B | 126 M | 516 M |
Quarterly Total Assets Amarin Corporation plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 670 M | 656 M | 685 M | 751 M | 800 M | 790 M | 832 M | 839 M | 860 M | 860 M | 886 M | 908 M | - | 974 M | 1.07 B | 1.04 B | 1.04 B | 990 M | 966 M | 966 M | 966 M | 966 M | 882 M | 882 M | 882 M | 882 M | 386 M | 386 M | 386 M | 386 M | 162 M | 162 M | 162 M | 162 M | 167 M | 167 M | 167 M | 167 M | 173 M | 173 M | 173 M | 172 M | 171 M | 171 M | 171 M | 171 M | 252 M | 252 M | 252 M | 252 M | 311 M | 311 M | 311 M | 311 M | 126 M | 126 M | 126 M | 126 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 B | 126 M | 509 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
1.08 B | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 8.57 | -1.95 % | $ 1.39 B | Britain |
 |
Certara
CERT
|
1.56 B | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
1.1 B | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
45.6 M | $ 18.1 | 1.17 % | $ 869 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Eton Pharmaceuticals
ETON
|
31.7 M | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
58.7 M | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
4.14 B | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
4.09 M | $ 27.98 | 2.15 % | $ 364 M | USA |
 |
Galecto
GLTO
|
38.2 M | $ 29.63 | -1.39 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.76 | -6.37 % | $ 17.6 B | Danmark |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
149 M | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
2.53 B | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
Hoth Therapeutics
HOTH
|
7.71 M | $ 1.01 | -0.98 % | $ 6.44 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
45.1 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
24.9 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Immunic
IMUX
|
24.1 M | $ 1.12 | 5.19 % | $ 174 M | USA |
 |
Agenus
AGEN
|
314 M | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Immunovant
IMVT
|
776 M | $ 27.24 | -1.84 % | $ 4.13 B | USA |
 |
Inhibrx
INBX
|
308 M | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
14.1 M | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
57 M | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
2.26 B | $ 147.23 | 0.62 % | $ 29.3 B | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |